Medexus Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Medexus Pharmaceuticals has a total shareholder equity of $32.7M and total debt of $42.5M, which brings its debt-to-equity ratio to 129.8%. Its total assets and total liabilities are $145.4M and $112.6M respectively. Medexus Pharmaceuticals's EBIT is $12.8M making its interest coverage ratio 1.4. It has cash and short-term investments of $7.0M.
Key information
129.8%
Debt to equity ratio
US$42.50m
Debt
| Interest coverage ratio | 1.4x |
| Cash | US$6.97m |
| Equity | US$32.74m |
| Total liabilities | US$112.63m |
| Total assets | US$145.37m |
Recent financial health updates
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Nov 05
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden
Apr 25Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 11Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky
Jan 19Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 22Recent updates
Investors Appear Satisfied With Medexus Pharmaceuticals Inc.'s (TSE:MDP) Prospects As Shares Rocket 52%
Jan 19After Leaping 31% Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Are Not Flying Under The Radar
Dec 05Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Nov 05There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings
Aug 19Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 10Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth
Jul 31The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet
Jun 15Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden
Apr 25Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive
Mar 03Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story
Jan 06Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors
Oct 11Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 11Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky
Jan 19Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 22Financial Position Analysis
Short Term Liabilities: MDP's short term assets ($64.2M) exceed its short term liabilities ($63.4M).
Long Term Liabilities: MDP's short term assets ($64.2M) exceed its long term liabilities ($49.2M).
Debt to Equity History and Analysis
Debt Level: MDP's net debt to equity ratio (108.5%) is considered high.
Reducing Debt: MDP's debt to equity ratio has increased from 70.4% to 129.8% over the past 5 years.
Debt Coverage: MDP's debt is well covered by operating cash flow (52.2%).
Interest Coverage: MDP's interest payments on its debt are not well covered by EBIT (1.4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 04:12 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medexus Pharmaceuticals Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |